CD8A and neoplasm: In this context, Neu-targeted vaccines, which raise strong CD8-T cell responses to a dominant peptide (RNEU420-429) in (non-tolerized) WT FVB/N mice and protect them from a neu-expressing tumor challenge, fail to do so in neu-transgenic mice.